Technical Analysis for BBIO - BridgeBio Pharma, Inc.

Grade Last Price % Change Price Change
grade F 18.635 2.33% 0.43
BBIO closed down 1.62 percent on Friday, October 18, 2019, on 74 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Flat
See historical BBIO trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 2.33%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.33%
Narrow Range Bar Range Contraction 2.33%
NR7 Range Contraction 2.33%
Inside Day Range Contraction 2.33%
Wide Bands Range Expansion 2.33%
Oversold Stochastic Weakness 2.33%
1,2,3 Retracement Bearish Bearish Swing Setup 0.68%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.68%
MACD Bullish Signal Line Cross Bullish 0.68%

Older signals for BBIO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
Organ Systems Anatomy Tyrosine Kinase Receptors Protein Kinase Inhibitor Cardiomyopathy Tyrosine Kinase Familial Amyloid Polyneuropathy Hyperplasia Achondroplasia Congenital Adrenal Hyperplasia Fibroblast Growth Factor Receptor Transthyretin TTR Amyloidosis
Is BBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.94
52 Week Low 17.61
Average Volume 286,124
200-Day Moving Average 0.0
50-Day Moving Average 24.9795
20-Day Moving Average 20.2613
10-Day Moving Average 18.585
Average True Range 1.5646
ADX 36.51
+DI 10.3743
-DI 25.8087
Chandelier Exit (Long, 3 ATRs ) 23.6688
Chandelier Exit (Short, 3 ATRs ) 22.3038
Upper Bollinger Band 25.2658
Lower Bollinger Band 15.2568
Percent B (%b) 0.3
BandWidth 49.399594
MACD Line -2.0646
MACD Signal Line -2.1618
MACD Histogram 0.0972
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.20
Resistance 3 (R3) 19.19 18.84 19.04
Resistance 2 (R2) 18.84 18.59 18.85 18.98
Resistance 1 (R1) 18.53 18.44 18.36 18.54 18.92
Pivot Point 18.18 18.18 18.10 18.19 18.18
Support 1 (S1) 17.87 17.93 17.70 17.88 17.50
Support 2 (S2) 17.52 17.78 17.53 17.44
Support 3 (S3) 17.21 17.52 17.39
Support 4 (S4) 17.22